Cargando…
Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells
Malignant mesothelioma (MM) is an aggressive malignant neoplasm which rapidly invades pleural tissues and has a poor prognosis. Here, we explore enhancement of the effect of irinotecan [camptothecin‐11 (CPT‐11)] by the p53‐dependent induction of carboxylesterase 2 (CES2), a CPT‐11‐activating enzyme,...
Autores principales: | Han, Bo, Lee‐Okada, Hyeon‐Cheol, Ishimine, Momoko, Orita, Hajime, Nishikawa, Keiko, Takagaki, Tetsuya, Kajino, Kazunori, Yokomizo, Takehiko, Hino, Okio, Kobayashi, Toshiyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609812/ https://www.ncbi.nlm.nih.gov/pubmed/32961616 http://dx.doi.org/10.1002/2211-5463.12985 |
Ejemplares similares
-
The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer
por: Ishimine, Momoko, et al.
Publicado: (2018) -
Induction by rapamycin and proliferation‑promoting activity of Hspb1 in a Tsc2‑deficient cell line
por: Kitano, Takayuki, et al.
Publicado: (2023) -
Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016) -
ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
por: ITO, TOMOAKI, et al.
Publicado: (2014) -
Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020)